自主研发：国内首款抗TL1A单抗临床试验申请获CDE受理

TL1A-DR3通路在炎症性肠病（IBD）中通过激活免疫细胞释放炎症因子导致肠道炎症加重，其表达水平与IBD病情相关，开发可抑制TL1A-DR3信号通路的抑制剂药物已经成为IBD治疗策略。

MNC针对TL1A管线布局（含合作交易）

从药物开发市场来看，2023上半年来针对TL1A靶点自免研究及开发取得显著进展。随着自身免疫疾病领域热度不断上升，跨国药企们对IBD领域的关注度也越来越高：截至目前，IBD领域已达成数项大额重磅交易，参与方包括默沙东、罗氏、赛诺菲、艾伯维等药企，表明其在收购这条路上越走越宽，这也一定程度反映出TL1A靶点高市场热度以及MNC药企的发展策略。值得注意的是，美东时间2024年12月17日，赛诺菲与Teva共同宣布，在溃疡性结肠炎（UC）和克罗恩病（CD）患者中开展针对Duvakitug（TEV-574/SAR447189）的2b期RELIEVE UCCD研究达到主要终点。RELIEVE UCCD是一项为期14周的2b期随机、双盲、剂量范围研究，结果显示：在第14周，UC患者中Duvakitug低剂量和高剂量组的临床缓解率分别为36.2%和47.8%，显著高于安慰剂组的20.45%（p=0.050和0.003）。CD患者中，低剂量和高剂量组分别为26.1%和47.8%，显著高于安慰剂组的13.0%（p=0.058和<0.001）。此外，Duvakitug在UC和CD中耐受性总体良好，未发现不良事件。此外，根据其公布内容显示，Duvakitug在溃疡性结肠炎（UC）和克罗恩病（CD）在高剂量治疗中的主要终点结果在目前所有TL1A单克隆抗体中疗效最佳。

产品推荐：点击查看IBD热门靶点药物开发工具

ACROBiosystems百普赛斯从“为更好生物医药”出发，为满足炎症性肠病（IBD）生物药开发需求，推出满足从分子层面到细胞层面药物开发应用的一系列高品质生物药开发工具。

• TL1A : DR3 (ELISA) 抑制剂筛选试剂盒：专为检测和筛选TL1A-DR3信号通路抑制剂而设计，能有效定量评估候选分子对TL1A与其受体DR3结合的抑制效果。该试剂盒灵敏度高、特异性强，适用于药物开发中的高通量筛选，帮助研究人员快速筛选出具有潜力的TL1A靶向抑制剂，为炎症性肠病等相关疾病的生物治疗提供有力支持。

• TL1A-DR3 (TR-FRET) 抑制检测试剂盒：通过时间分辨荧光共振能量转移（TR-FRET）技术，定量检测TL1A与DR3之间的相互作用。该试剂盒灵敏度高、背景干扰低，适用于筛选潜在的TL1A-DR3信号通路抑制剂。

The purity of Human DLL3, His Tag (Cat. No. TLA-M5243) is greater than 90% verified by SDS-PAGE and more than 90% verified by SEC-MALS.

Immobilized Cynomolgus/Rhesus macaque TL1A / TNFSF15, His Tag (Cat. No. TLA-C5241) at 5 μg/mL (100 μL/well) can bind Human DcR3, Fc Tag (Cat. No. TNB-H5255) with a linear range of 0.2-10 ng/mL (QC tested).

点击申请Protocol

Biotinylated Human TL1A Protein, His,Avitag (Cat. No. TLA-H52Q1) immobilized on SA Chip can bind Human DR3 Protein, His Tag (Cat. No. TN5-H52H3) with an affinity constant of 2.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

点击申请Protocol

Loaded Human DcR3, Fc Tag (Cat. No. TNB-H5255) on AHC Biosensor, can bind Human LIGHT, Mouse IgG2a Fc Tag, low endotoxin (Cat. No. LIT-H5256) with an affinity constant of 1.64 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

点击申请Protocol

Response to human TL1A protein (FOLD).

This reporter cell （Cat. No. SCJUR-STF178）was incubated with serial dilutions of human  TL1A protein (Cat. No. TLA-H5243). The max induction fold was approximately 40.12.

点击申请Protocol

Serial dilutions of Human Anti-TL1A Neutralizing antibody (Cat. No. EP168) (1:1 serial dilution, from 20μg/mL to 0.3125μg/mL) was added into Human DR3: Biotinylated Human TL1A (Cat. No. EP168) 　binding reactions. The assay was performed according to the protocol described below. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).

For each experiment, a standard curve needs to be set for each micro-plate, and the specific OD value may vary depending on different laboratories, testers, or equipments. The example data is for reference only.

更多热门自免疾病靶点产品推荐